On this page

DIPHENHYDRAMINE HYDROCHLORIDE

Prescription ANDA TE AA RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
DIPHENHYDRAMINE HYDROCHLORIDE
Generic name
Diphenhydramine Hydrochloride
Dosage form
Solution
Route
Oral
Marketing category
ANDA · ANDA
Labeler
Camber Pharmaceuticals, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
6
Packages
8
Data completeness
83% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Diphenhydramine Hydrochloride 12.5 mg/5mL 1049630 View
Diphenhydramine Hydrochloride 25 mg/10mL 1049630 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution
Route of administration
Oral
Presentations
14

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Histamine H1 Receptor Antagonists [MoA] MoA All 136 members
Histamine-1 Receptor Antagonist [EPC] EPC All 134 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
087513
Application type
ANDA · Abbreviated New Drug Application
Approval date
February 10, 1982
Sponsor
PHARM ASSOC
Products on application
1
Submissions recorded
10
Products approved under application 087513.
Product Trade name Form Strength Ingredient Status TE Flags
087513-001 DIPHENHYDRAMINE HYDROCHLORIDE ELIXIR DIPHENHYDRAMINE HYDROCHLORIDE Prescription AA RLD RS

Therapeutic equivalence

Source: Orange Book
TE code
AA
Reference Listed Drug
Yes
Reference Standard
Yes

What this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 087513.
Type No. Action Status Date Review
Supplement 14 Manufacturing (CMC) Approved March 17, 2020 —
Supplement 12 Labeling Approved June 10, 2009 —
Supplement 10 Labeling Approved March 20, 1996 —
Supplement 7 Manufacturing (CMC) Approved November 12, 1991 —
Supplement 9 Labeling Approved November 21, 1990 —
Supplement 8 Labeling Approved April 12, 1990 —
Supplement 6 Labeling Approved September 14, 1988 —
Supplement 5 Labeling Approved July 25, 1988 —
Supplement 3 Manufacturing (CMC) Approved September 9, 1987 —
Original application 1 Approved February 10, 1982 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260704). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260704 HUMAN OTC DRUG · 20250327 HUMAN PRESCRIPTION DRUG · 20240405

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Diphenhydramine hydrochloride in the oral form is effective for the following indications: Antihistaminic For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Motion Sickness For active and prophylactic treatment of motion sickness. Antiparkinsonism For parkinsonism (including drug-induced) in the elderly unable to tolerate more potent agents; mild cases of parkinsonism (including drug-induced) in other age groups; in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents. Nighttime Sleep-aid.

Principal Display Panel Oncor Pharmaceuticals NDC 83720-502-16 Diphenhydramine Hydrochloride Oral Solution 12.5 mg/5 ml Antihistamine Cherry Flavor RELIEVES - Sneezing - Itchy, Watery Eyes - Runny Nose - Itchy Throat due to Allergies DO NOT USE IF TAMPER EVIDENT SEAL UNDER CAP IS BROKEN OR MISSING Alcohol Free NET WT. 16 OZ. (473 ml) NDC 83720-502-04 Diphenhydramine Hydrochloride Oral Solution 12.5 mg/5 ml Antihistamine Cherry Flavor RELIEVES - Sneezing - Itchy, Watery Eyes - Runny Nose - Itchy Throat due to Allergies DO NOT USE IF TAMPER EVIDENT SEAL UNDER CAP IS BROKEN OR MISSING Alcohol Free NET WT. 4 OZ. (118 ml) Manufactured In USA For : Oncor Pharmaceuticals 6755 Business Pkwy Suite 202 Elkridge, MD 21075 United States. Rev. 03/25

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT. A single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. The duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours. Adults 25 to 50 mg three to four times daily. The nightime sleep aid dosage is 50 mg at bedtime. Pediatric Patients, other than premature infants and neonates 12.5 mg to 25 mg three or four times daily. Maximum daily dosage not to exceed 300 mg. For physicians who wish to calculate the dose on the basis of body weight or surface area, the recommended dosage is 5 mg/kg/24 hours or 150 mg/m 2 /24 hours. Data are not available on the use of diphenhydramine hydrochloride as a nighttime sleep-aid in children under 12 years. The basis for determining the most effective dosage regimen will be the response of the patient to medication and the condition under treatment. In motion sickness, full dosage is recommended for prophylactic use, the first dose to be given 30 minutes before exposure to motion and similar doses before meals and upon retiring for the duration of exposure

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Use in Neonates or Premature Infants This drug should not be used in neonates or premature infants. Use in Nursing Mothers Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. Antihistamines are also contraindicated in the following conditions Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.

WARNINGS Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction. Use in Pediatric Patients In pediatric patients, especially, antihistamines in overdosage may cause hallucinations, convulsions, or death. As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young pediatric patient, particularly, they may produce excitation. Use in the Elderly (approximately 60 years or older) Antihistamines are most likely to cause dizziness, sedation, and hypotension in elderly patients.

Ask a Doctor

openFDA Drug Labeling

Ask a doctor before use if you have - glaucoma - trouble urinating due to an enlarged prostate gland - a breathing problem such as emphysema or chronic bronchitis

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The most frequent adverse reactions are underscored. 1. General: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of the mouth, nose and throat. 2. Cardiovascular System: Hypotension, headache, palpitations, tachycardia, extrasystoles. 3. Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis. 4. Nervous System: Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions. 5. GI System: Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation. 6. GU System: Urinary frequency, difficult urination, urinary retention, early menses. 7. Respiratory System: Thickening of bronchial secretions, tightness of chest or throat and wheezing, nasal stuffiness. To report SUSPECTED ADVERSE REACTIONS, contact Annora Pharma Limited at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

openFDA Drug Labeling

Drug Interactions Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

Description

openFDA Drug Labeling

DESCRIPTION Diphenhydramine hydrochloride USP is an antihistamine drug having the chemical name 2-(diphenylmethoxy)-N,N-dimethylethanamine hydrochloride and has the molecular formula C 17 H 21 NO•HCl (molecular weight 291.82). It occurs as a white, odorless, crystalline powder. Slowly darkens on exposure to light and is freely soluble in water, alcohol and in chloroform. Sparingly soluble in acetone. Very slightly soluble in benzene and in ether. The structural formula is as follows: Each 5 mL contains 12.5 mg of diphenhydramine hydrochloride USP and alcohol 14% for oral administration. Inactive Ingredients: cassia cinnamon flavour (contains cassia bark oil, cinnamic aldehyde, cinnamon leaf oil, eugenol and glyceryl triacetate), citric acid monohydrate, D&C red No. 33, ethyl alcohol dehydrated, FD&C red No. 40, purified water, sucrose and trisodium citrate dihydrate. diphenhydraminehclstruct

Active Ingredient

openFDA Drug Labeling

Active ingredients (in each 5 mL teaspoonful) Purpose Diphenhydramine Hydrochloride 12.5mg .............................Antihistamine

OVERDOSAGE Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in pediatric patients. Atropine-like signs and symptoms, dry mouth; fixed, dilated pupils; flushing and gastrointestinal symptoms may also occur. If vomiting has not occurred spontaneously , the patient should be induced to vomit. This is best done by having him drink a glass of water or milk after which he should be made to gag. Precaution against aspiration must be taken, especially in infants and children. If vomiting is unsuccessful , gastric lavage is indicated within 3 hours after ingestion and even later if large amounts of milk or cream were given beforehand. Isotonic or 1/2 isotonic saline is the lavage solution of choice. Saline cathartics , as milk of magnesia, by osmosis draw water into the bowel and therefore are valuable for their action in rapid dilution of bowel content. Stimulants should not be used. Vasopressors may be used to treat hypotension.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Each 5 mL of Diphenhydramine Hydrochloride Oral Solution, USP- Clear, purple to red solution with cinnamon flavour, contains 12.5 mg diphenhydramine hydrochloride with 14% alcohol and is supplied as: NDC 31722-600-11 118 mL (4 oz) bottle NDC 31722-600-31 Box of 100 (10 cartons containing 10 x 5 mL unit dose cups in each.) NDC 31722-601-31 Box of 100 (10 cartons containing 10 x 10 mL unit dose cups in each.) STORAGE Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from freezing and light. Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854. By: Annora Pharma Pvt. Ltd. Sangareddy - 502313, Telangana, India. Revised: 05/2026 camberlogo

Adverse event reports

Source: openFDA FAERS
172,003
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: DIPHENHYDRAMINE HYDROCHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II June 15, 2022 Mckesson Medical-Surgical Inc. Corporate Office cGMP deviations: Temperature abuse Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
31722-600-11 31722-600 Camber Pharmaceuticals, Inc. 1 BOTTLE in 1 CARTON (31722-600-11) / 118 mL in 1 BOTTLE June 17, 2026
31722-600-31 31722-600 Camber Pharmaceuticals, Inc. 10 CARTON in 1 BOX (31722-600-31) / 10 CUP, UNIT-DOSE in 1 CARTON / 5 mL in 1 CUP, UNIT-DOSE June 17, 2026
31722-601-31 31722-601 Camber Pharmaceuticals, Inc. 10 CARTON in 1 BOX (31722-601-31) / 10 CUP, UNIT-DOSE in 1 CARTON / 10 mL in 1 CUP, UNIT-DOSE June 17, 2026
71872-7242-1 71872-7242 Medical Purchasing Solutions, LLC 1 CUP, UNIT-DOSE in 1 BAG (71872-7242-1) / 10 mL in 1 CUP, UNIT-DOSE March 1, 2021
83720-502-04 83720-502 Oncor Pharmaceuticals 118 mL in 1 BOTTLE (83720-502-04) March 27, 2025
83720-502-16 83720-502 Oncor Pharmaceuticals 473 mL in 1 BOTTLE (83720-502-16) March 27, 2025
0121-0489-00 0121-0489 PAI Holdings, LLC dba PAI Pharma 10 TRAY in 1 CASE (0121-0489-00) / 10 CUP, UNIT-DOSE in 1 TRAY / 5 mL in 1 CUP, UNIT-DOSE (0121-0489-05) February 10, 1982
0121-0978-00 0121-0978 PAI Holdings, LLC dba PAI Pharma 10 TRAY in 1 CASE (0121-0978-00) / 10 CUP, UNIT-DOSE in 1 TRAY / 10 mL in 1 CUP, UNIT-DOSE (0121-0978-10) February 10, 1982
31722-600 31722-600 Camber Pharmaceuticals, Inc. — June 17, 2026
31722-601 31722-601 Camber Pharmaceuticals, Inc. — June 17, 2026
71872-7242 71872-7242 Medical Purchasing Solutions, LLC — February 10, 1982
83720-502 83720-502 Oncor Pharmaceuticals — March 27, 2025
0121-0489 0121-0489 PAI Holdings, LLC dba PAI Pharma — February 10, 1982
0121-0978 0121-0978 PAI Holdings, LLC dba PAI Pharma — February 10, 1982

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 13 sections on this page.